Having trouble accessing articles? Reset your cache.

FDA denies Endo petition

FDA denied a 2012 Citizen's Petition from Endo Health Solutions Inc. (NASDAQ:ENDP) asking the agency to determine that the original formulation of the company's pain drug Opana ER oxymorphone

Read the full 298 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE